China's Akeso Out-licenses Immuno-Oncology mAb to Merck

Akeso Biopharma, located in Zhongshan, Guangdong province, has out-licensed global rights for an immuno-oncology antibody to Merck (known as MSD outside of the United States and Canada). Merck paid an unspecified upfront payment and agreed to a package of up to $200 million in development and commercialization milestones. AK-107 is an immune checkpoint blocking antibody discovered by Akeso. Further details were not disclosed. More details.... Stock Symbol: (NYSE:MRK) Share this with colleagues: // //